多发性硬化症的疾病修饰疗法
Disease Modifying Therapy in Multiple Sclerosis.
作者信息
Williams U E, Oparah S K, Philip-Ephraim E E
机构信息
Internal Medicine Department, University of Calabar, Calabar 540242, Cross River State, Nigeria.
出版信息
Int Sch Res Notices. 2014 Jul 7;2014:307064. doi: 10.1155/2014/307064. eCollection 2014.
Abstract
Multiple sclerosis is an autoimmune disease of the central nervous system characterized by inflammatory demyelination and axonal degeneration. It is the commonest cause of permanent disability in young adults. Environmental and genetic factors have been suggested in its etiology. Currently available disease modifying drugs are only effective in controlling inflammation but not prevention of neurodegeneration or accumulation of disability. Search for an effective neuroprotective therapy is at the forefront of multiple sclerosis research.
摘要
多发性硬化症是一种中枢神经系统的自身免疫性疾病，其特征为炎性脱髓鞘和轴突变性。它是年轻成年人永久性残疾的最常见原因。病因学研究表明其发病与环境和遗传因素有关。目前可用的疾病修饰药物仅能有效控制炎症，但无法预防神经退行性变或残疾的累积。寻找有效的神经保护疗法是多发性硬化症研究的前沿课题。
相似文献
1
Disease Modifying Therapy in Multiple Sclerosis.多发性硬化症的疾病修饰疗法
Int Sch Res Notices. 2014 Jul 7;2014:307064. doi: 10.1155/2014/307064. eCollection 2014.
2
Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.调节中枢神经系统内的过程对于多发性硬化症的治疗控制至关重要。
J Neurol. 2005 Nov;252 Suppl 5:v38-45. doi: 10.1007/s00415-005-5007-2.
3
Neuronal injury in chronic CNS inflammation.慢性中枢神经系统炎症中的神经元损伤。
Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):551-62. doi: 10.1016/j.bpa.2010.11.001. Epub 2010 Nov 29.
4
Axonal pathology in multiple sclerosis: relationship to neurologic disability.多发性硬化症中的轴突病理学：与神经功能障碍的关系。
Curr Opin Neurol. 1999 Jun;12(3):295-302. doi: 10.1097/00019052-199906000-00008.
5
Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis.多发性硬化症中急性轴索损伤、华勒氏变性与临床残疾的关系。
J Neuroinflammation. 2017 Mar 17;14(1):57. doi: 10.1186/s12974-017-0831-8.
6
Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.多发性硬化症的神经保护：未来十年的治疗挑战。
Pharmacol Ther. 2010 Apr;126(1):82-93. doi: 10.1016/j.pharmthera.2010.01.006. Epub 2010 Feb 1.
7
Update on disease-modifying therapies for multiple sclerosis.多发性硬化症疾病修正疗法的最新进展。
J Investig Med. 2017 Jun;65(5):883-891. doi: 10.1136/jim-2016-000339. Epub 2017 Jan 27.
8
Neurodegeneration and neuroprotective agents in multiple sclerosis.多发性硬化症中的神经退行性变与神经保护剂
Recent Pat CNS Drug Discov. 2008 Nov;3(3):153-65. doi: 10.2174/157488908786242498.
9
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.继发进展型多发性硬化症的药物治疗：概述。
CNS Drugs. 2018 Jun;32(6):499-526. doi: 10.1007/s40263-018-0538-0.
10
Promoting return of function in multiple sclerosis: An integrated approach.促进多发性硬化症的功能恢复：一种综合方法。
Mult Scler Relat Disord. 2013 Oct 1;2(4). doi: 10.1016/j.msard.2013.04.002.
引用本文的文献
1
Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic Neuropathy.无视神经病变病史的多发性硬化症患者眼部黄斑区视网膜内层的结构和功能评估
J Clin Med. 2025 Aug 21;14(16):5919. doi: 10.3390/jcm14165919.
2
Can Vitamin D Reduce Inflammation? The Influence of Supplementation on Selected Immunological Markers.维生素 D 能减轻炎症吗？补充剂对某些免疫标志物的影响。
Int J Mol Sci. 2024 Jul 11;25(14):7592. doi: 10.3390/ijms25147592.
3
Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy.多发性硬化症伴视神经病变史患者黄斑区视网膜内层结构与功能损害的地形学相关性
J Clin Med. 2023 Nov 19;12(22):7175. doi: 10.3390/jcm12227175.
4
Prioritizing Components of a Dyadic Physical Activity Intervention for People With Moderate to Severe Multiple Sclerosis and Their Care Partners: A Modified e-Delphi Study.为中重度多发性硬化症患者及其护理伙伴确定二元体育活动干预的组成部分优先级：一项改良的电子德尔菲研究。
Int J MS Care. 2023 Jan-Feb;25(1):8-14. doi: 10.7224/1537-2073.2021-079. Epub 2022 Jul 5.
5
Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells' Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration.多焦视网膜电图明视负反应：一种可靠的检测范式，用于检测作为视网膜神经变性模型的多发性硬化所致球后视神经炎中局部视网膜神经节细胞的损伤。
Diagnostics (Basel). 2022 May 6;12(5):1156. doi: 10.3390/diagnostics12051156.
6
Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis.多发性硬化中外层和中层黄斑层的功能评估
J Clin Med. 2020 Nov 22;9(11):3766. doi: 10.3390/jcm9113766.
7
Morphological Outer Retina Findings in Multiple Sclerosis Patients With or Without Optic Neuritis.患有或未患有视神经炎的多发性硬化症患者的视网膜外层形态学表现
Front Neurol. 2020 Sep 15;11:858. doi: 10.3389/fneur.2020.00858. eCollection 2020.
8
Adherence to Disease-Modifying Therapies in Patients With MS: A Retrospective Cohort Study.多发性硬化症患者对疾病修正疗法的依从性：一项回顾性队列研究。
Fed Pract. 2016 May;33(5):43-45.
9
Effect of Comorbidities on Outcomes of Neurorehabilitation Interventions in Multiple Sclerosis: A Scoping Review.共病对多发性硬化症神经康复干预结果的影响：一项范围综述
Int J MS Care. 2016 Nov-Dec;18(6):282-290. doi: 10.7224/1537-2073.2016-015.
本文引用的文献
1
Fingolimod.芬戈莫德
Neurol Clin Pract. 2011 Dec;1(1):61-65. doi: 10.1212/CPJ.0b013e31823c51dd.
2
Disease-specific therapy of idiopathic inflammatory demyelinating disorders.特发性炎症性脱髓鞘疾病的特异性治疗。
Expert Rev Neurother. 2012 Sep;12(9):1113-24. doi: 10.1586/ern.12.101.
3
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.安慰剂对照的口服 BG-12 或那他珠单抗治疗多发性硬化症的 3 期研究。
N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328.
4
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.随机试验口服特立氟胺治疗复发型多发性硬化症。
N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.
5
Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.多发性硬化症的疾病修正治疗的成本效益：一项基于人群的研究。
Neurology. 2011 Jul 26;77(4):355-63. doi: 10.1212/WNL.0b013e3182270402. Epub 2011 Jul 20.
6
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.芬戈莫德在多发性硬化症中的疗效和不良反应的机制。
Ann Neurol. 2011 May;69(5):759-77. doi: 10.1002/ana.22426.
7
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.多发性硬化症的诊断标准：2010 年麦克唐纳标准修订版。
Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.
8
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.芬戈莫德（FTY720）：一种治疗多发性硬化症的口服药物的发现和开发。
Nat Rev Drug Discov. 2010 Nov;9(11):883-97. doi: 10.1038/nrd3248. Epub 2010 Oct 29.
9
Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis.早期中枢萎缩率可预测多发性硬化症的 5 年临床结局。
J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1351-6. doi: 10.1136/jnnp.2009.199968. Epub 2010 Sep 8.
10
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.多发性硬化症：危险因素、前驱症状和潜在的因果途径。
Lancet Neurol. 2010 Jul;9(7):727-39. doi: 10.1016/S1474-4422(10)70094-6.
Zotero 插件